The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.

Mechanism / theoretical grounding — not clinical validation.

Gatta M, Dovizio M, Milillo C, Ruggieri AG, Sallese M, Antonucci I, Trofimov A, Khavinson V, Trofimova S, Bruno A, Ballerini P. Stem Cell Rev Rep. 2025.

Organ: retina-vision · Type: in-vitro · Peptides: Epitalon

PMID: 40493162

In high-glucose-injured ARPE-19 cells, Epitalon restored delayed wound closure and limited EMT and fibrosis markers — an in-vitro diabetic-retinopathy model, not a patient trial.

Editorial summary of a 2025 original article in Stem Cell Reviews and Reports (open access via PMC: doi:10.1007/s12015-025-10911-x). Public pages cite PubMed; the DOI is the publisher/OA record. Read the paper: PMID 40493162.

Methods

High-glucose (HG) injury of a human retinal pigment epithelial cell line (ARPE-19) as an in-vitro model of delayed healing in diabetic retinopathy. The authors measured wound closure, intracellular ROS, antioxidant-gene expression, epithelial–mesenchymal transition (EMT), and fibrosis-related genes, with or without the tetrapeptide AEDG (Epitalon). Culture conditions belong in the primary text.

Findings

HG delayed wound healing, raised ROS, and decreased antioxidant-gene expression. HG also induced EMT and upregulated fibrosis-related genes; the authors suggest HG-induced EMT contributes to subretinal fibrosis, an end-stage of several eye diseases including proliferative diabetic retinopathy. Epitalon restored impaired wound healing in HG-injured ARPE-19 cells and inhibited hyperglycemia-induced EMT and fibrosis in this system. The authors call for more mechanistic work and for ophthalmic formulations; that is a research suggestion, not a licensed therapy.

ARPE-19 is not a patient. This is not evidence that Epitalon treats diabetic retinopathy. Follow the PMID and the OA DOI.